Cyclo Therapeutics Inc
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials fo… Read more
Cyclo Therapeutics Inc (CYTH) - Total Liabilities
Latest total liabilities as of September 2024: $18.73 Million USD
Based on the latest financial reports, Cyclo Therapeutics Inc (CYTH) has total liabilities worth $18.73 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cyclo Therapeutics Inc - Total Liabilities Trend (2000–2024)
This chart illustrates how Cyclo Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cyclo Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Cyclo Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Rma Global Ltd
AU:RMY
|
Australia | AU$10.41 Million |
|
ST Dupont
PA:DPT
|
France | €30.70 Million |
|
Four Leaf Acquisition Corporation Class A Common Stock
NASDAQ:FORL
|
USA | $26.89 Million |
|
Bliss Properti Indonesia Tbk PT
JK:POSA
|
Indonesia | Rp1.19 Trillion |
|
Arrow Minerals Ltd
AU:AMD
|
Australia | AU$1.91 Million |
|
Maritime Launch Services Inc.
OTCQB:MAXQF
|
USA | $20.42 Million |
|
Manganese X Energy Corp
OTCQB:MNXXF
|
USA | $59.62K |
|
VL E-Governance & IT Solutions Limited
NSE:VLEGOV
|
India | ₹-456.97 Million |
Liability Composition Analysis (2000–2024)
This chart breaks down Cyclo Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cyclo Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cyclo Therapeutics Inc (2000–2024)
The table below shows the annual total liabilities of Cyclo Therapeutics Inc from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $8.49 Million | 0.00% |
| 2023-12-31 | $8.49 Million | +143.93% |
| 2022-12-31 | $3.48 Million | -9.57% |
| 2021-12-31 | $3.85 Million | +3.04% |
| 2020-12-31 | $3.74 Million | +17.57% |
| 2019-12-31 | $3.18 Million | +65.02% |
| 2018-12-31 | $1.93 Million | +104.16% |
| 2017-12-31 | $943.03K | +175.30% |
| 2016-12-31 | $342.54K | -66.14% |
| 2015-12-31 | $1.01 Million | +10.54% |
| 2014-12-31 | $915.14K | -7.97% |
| 2013-12-31 | $994.38K | -7.03% |
| 2012-12-31 | $1.07 Million | -21.69% |
| 2011-12-31 | $1.37 Million | +158.19% |
| 2010-12-31 | $528.99K | +464.70% |
| 2009-12-31 | $93.68K | +29.88% |
| 2008-12-31 | $72.12K | -69.32% |
| 2007-12-31 | $235.07K | +17.33% |
| 2006-12-31 | $200.35K | +7.43% |
| 2005-12-31 | $186.49K | -57.80% |
| 2004-12-31 | $441.95K | +48.95% |
| 2003-12-31 | $296.70K | +1.10% |
| 2002-12-31 | $293.48K | -32.92% |
| 2001-12-31 | $437.50K | -5.56% |
| 2000-12-31 | $463.27K | -- |